IMNM240719P22500
- 3.53
- 0.000.00%
Immunome Newsroom
Express News | Immunome Appoints Phil Tsai as Chief Technical Officer
Immunome Initiated at Overweight by Piper Sandler
Immunome Initiated at Overweight by Piper Sandler
Immunome (IMNM.US) was first covered by Piper Sandler, which gave it an increase rating, and the target price was $27.00.
Immunome (IMNM.US) was first covered by Piper Sandler, which gave it an increase rating, and the target price was $27.00.
Piper Sandler Initiates Coverage On Immunome With Overweight Rating, Announces Price Target of $27
Piper Sandler analyst Biren Amin initiates coverage on Immunome (NASDAQ:IMNM) with a Overweight rating and announces Price Target of $27.
Immunome Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 87.5% Piper Sandler → $27 Initiates Coverage On → Overweight 04/30/2024 66.67% JP Morgan → $24
Bullish Immunome Insiders Loaded Up On US$2.67m Of Stock
Over the last year, a good number of insiders have significantly increased their holdings in Immunome, Inc. (NASDAQ:IMNM). This is encouraging because it indicates that insiders are more optimistic ab
Immunome (NASDAQ:IMNM): An Opportunity for Investors With Strong Stomachs
Immunome(IMNM.US) Director Buys US$27,139.8 in Common Stock
$Immunome(IMNM.US)$ Director BIENAIME JEAN JACQUES purchased 2,000 shares of common stock on May 21, 2024 at an average price of $13.5699 for a total value of $27,139.8.Source: Announcement What is st
Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades.When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the sto
Immunome Shares Are Trading Higher After a Form4 Filing Showed President and CEO Clay Siegall Bought 100,000 Shares at an Average Price of $13.88 per Share.
Immunome Shares Are Trading Higher After a Form4 Filing Showed President and CEO Clay Siegall Bought 100,000 Shares at an Average Price of $13.88 per Share.
Immunome(IMNM.US) Officer Buys US$1.39 Million in Common Stock
$Immunome(IMNM.US)$ Officer SIEGALL CLAY B purchased 100K shares of common stock on May 20, 21, 2024 at an average price of $13.8807 for a total value of $1.39 million.Source: Announcement What is sta
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersRezolute (NASDAQ:RZLT) stock increased by 52.7% to $4.58 during Tuesday's after-market session. The company's market cap stands at $183.8 million. The company's, Q3 earnings came out 4 days ago
Immunome Form 4 Filing Shows President And CEO Clay B Siegall Bought 100,000 Shares Of Stock At A Price Of $13.88/Share
Immunome Form 4 Filing Shows President And CEO Clay B Siegall Bought 100,000 Shares Of Stock At A Price Of $13.88/Share
Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing
Clay B Siegall, Director, President and CEO, on May 20, 2024, executed a purchase for 100,000 shares in Immunome (IMNM) for $1,388,072. Following the Form 4 filing with the SEC, Siegall has control ov
Immunome Announces Completion of Purchase of Assets From Atreca
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion of its purchase of antibodies and related assets
Immunome Appoints CFO
Immunome Promotes Max Rosett To CFO, Effective May 9
Rosett most recently held the role of Executive Vice President, Operations, in addition to serving as Immunome's Interim Chief Financial Officer since January 2024.
Immunome Announces Promotion Of Max Rosett To Chief Financial Officer >IMNM
Immunome Announces Promotion Of Max Rosett To Chief Financial Officer >IMNM
Immunome's Promising Pipeline and Strategic Positioning Affirm Buy Rating
Immunome, Inc. Q1 Loss Increases, Misses Estimates